Effect of IL-6 on the insulin sensitivity in patients with type 2 diabetes

American Journal of Physiology - Endocrinology and Metabolism

Volumn 306, Issue 7, 2014, Pages

  Harder Lauridsen, N M ^a   Krogh Madsen, R ^a   Holst, J J ^b   Plomgaard, P ^a   Leick, L ^a   Pedersen, B K ^a   Fischer, C P ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Biopsy; Clamp technique; Humans; Inflammation; Insulin resistance; Interleukin 6; Metabolism; Muscle; Signal transducer and activator of transcription 3; Skeletal

Indexed keywords

CARBON DIOXIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HYDROCORTISONE; INTERLEUKIN 6; NEUTRAL INSULIN; PLACEBO; RECOMBINANT INTERLEUKIN 6; STABLE ISOTOPE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BODY MASS; CALORIMETRY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; ENERGY EXPENDITURE; FATTY ACID BLOOD LEVEL; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART RATE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSULIN SENSITIVITY; LYMPHOCYTE; MALE; MIDDLE AGED; MONOCYTE; MUSCLE BIOPSY; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; SYSTOLIC BLOOD PRESSURE;

BIOPSY; CLAMP TECHNIQUE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; METABOLISM; MUSCLE; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3; SKELETAL;

AGED; CALORIMETRY; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HORMONES; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; MIDDLE AGED; PLACEBOS; RECOMBINANT PROTEINS;

EID: 84900546488     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00571.2013     Document Type: Article

References (42)

1. Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 20: 3364-3375, 2006.
2. Bays HE. "Sick fat, " metabolic disease, atherosclerosis. Am J Med 122: S26-S37, 2009.
3. Bergstrom J. Muscle electrolytes in man determined by neutron activation analysis on needle biopsy specimens. SJCLA 0036-5513 1962.
4. Bortoluzzi S, Scannapieco P, Cestaro A, Danieli GA, Schiaffino S. Computational reconstruction of the human skeletal muscle secretome. Proteins 62: 776-792, 2006.
5. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55: 2688-2697, 2006.
6. da Silva KM, Bittencourt A, Homem de Bittencourt PI Jr, McClenaghan NH, Flatt PR, Murphy C, Newsholme P. Physiological concentrations of interleukin-6 directly promote insulin secretion, signal transduction, nitric oxide release, and redox status in a clonal pancreatic beta-cell line and mouse islets. J Endocrinol 214: 301-311, 2012.
7. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, Eppler E, Bouzakri K, Wueest S, Muller YD, Hansen AM, Reinecke M, Konrad D, Gassmann M, Reimann F, Halban PA, Gromada J, Drucker DJ, Gribble FM, Ehses JA, Donath MY. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17: 1481-1489, 2011.
8. Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53: 1643-1648, 2004.
9. Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance? Exerc Immunol Rev 12: 6-33, 2006.
10. Fischer CP, Hiscock NJ, Penkowa M, Basu S, Vessby B, Kallner A, Sjoberg LB, Pedersen BK. Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle. J Physiol 558: 633-645, 2004.
11. Fosgerau K, Galle P, Hansen T, Albrechtsen A, Rieper CL, Pedersen BK, Larsen LK, Thomsen AR, Pedersen O, Hansen MB, Steensberg A. Interleukin-6 autoantibodies are involved in the pathogenesis of a subset of type 2 diabetes. J Endocrinol 204: 265-273, 2010.
12. Glund S, Deshmukh A, Long YC, Moller T, Koistinen HA, Caidahl K, Zierath JR, Krook A. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes 56: 1630-1637, 2007.
13. Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, Thijs LG, Aarden LA. Increased plasma levels of interleukin-6 in sepsis. Blood 74: 1704-1710, 1989.
14. Hansen MB, Svenson M, Diamant M, Bendtzen K. Anti-interleukin-6 antibodies in normal human serum. Scand J Immunol 33: 777-781, 1991.
15. Hoene M, Runge H, Haring HU, Schleicher ED, Weigert C. Interleukin-6 promotes myogenic differentiation of mouse skeletal muscle cells: role of the STAT3 pathway. Am J Physiol Cell Physiol 304: C128-C136, 2013.
16. Jiang LQ, Duque-Guimaraes DE, Machado UF, Zierath JR, Krook A. Altered response of skeletal muscle to IL-6 in type 2 diabetic patients. Diabetes 62: 355-361, 2013.
17. Krarup T, Holst JJ. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept 9: 35-46, 1984.
18. Krogh-Madsen R, Plomgaard P, Moller K, Mittendorfer B, Pedersen BK. Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am J Physiol Endocrinol Metab 291: E108-E114, 2006.
19. Nieto-Vazquez I, Fernandez-Veledo S, de AC, Lorenzo M. Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes 57: 3211-3221, 2008.
20. Norheim F, Raastad T, Thiede B, Rustan AC, Drevon CA, Haugen F. Proteomic identification of secreted proteins from human skeletal muscle cells and expression in response to strength training. Am J Physiol Endocrinol Metab 301: E1013-E1021, 2011.
21. Olsen RH, Krogh-Madsen R, Thomsen C, Booth FW, Pedersen BK. Metabolic responses to reduced daily steps in healthy nonexercising men. J Am Med Assoc 299: 1261-1263, 2008.
22. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539, 1994.
23. Passonneau JV, Gatfield PD, Schulz DW, Lowry OH. An enzymic method for measurement of glycogen. Anal Biochem 19: 315-326, 1967.
24. Pedersen BK. The diseasome of physical inactivity-and the role of myokines in muscle-fat cross talk. J Physiol 587: 5559-5568, 2009.
25. Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA, Pedersen BK. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 288: E155-E162, 2005.
26. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 54: 2939-2945, 2005.
27. Scheele C, Nielsen S, Kelly M, Broholm C, Nielsen AR, Taudorf S, Pedersen M, Fischer CP, Pedersen BK. Satellite cells derived from obese humans with type 2 diabetes and differentiated into myocytes in vitro exhibit abnormal response to IL-6. PLoS One 7: e39657, 2012.
28. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52: 812-817, 2003.
29. Steensberg A, Fischer CP, Keller C, Moller K, Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 285: E433-E437, 2003.
30. Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van HG, Febbraio MA, Pedersen BK. Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 548: 631-638, 2003.
31. Steensberg A, van HG, Osada T, Sacchetti M, Saltin B, Klarlund PB. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529: 237-242, 2000.
32. Stith RD, Luo J. Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock 44: 210-215, 1994.
33. Stouthard JM, Romijn JA, Van der Poll T, Endert E, Klein S, Bakker PJ, Veenhof CH, Sauerwein HP. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol Endocrinol Metab 268: E813-E819, 1995.
34. Tsigos C, Papanicolaou DA, Defensor R, Mitsiadis CS, Kyrou I, Chrousos GP. Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology 66: 54-62, 1997.
35. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 82: 4167-4170, 1997.
36. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350, 2001.
37. van HG, Steensberg A, Fischer C, Keller C, Moller K, Moseley P, Pedersen BK. Interleukin-6 markedly decreases skeletal muscle protein turnover and increases nonmuscle amino acid utilization in healthy individuals. J Clin Endocrinol Metab 93: 2851-2858, 2008.
38. van HG, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, Pedersen BK. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88: 3005-3010, 2003.
39. Wolsk E, Mygind H, Grondahl TS, Pedersen BK, van HG. IL-6 selectively stimulates fat metabolism in human skeletal muscle. Am J Physiol Endocrinol Metab 299: E832-E840, 2010.
40. World Health Organization. Obesity-One of the greatest public health challenges. http://www.euro.who.int/en/what-we-do/health-topics/noncommunicablediseases/ obesity.2013.
41. Yoon JH, Yea K, Kim J, Choi YS, Park S, Lee H, Lee CS, Suh PG, Ryu SH. Comparative proteomic analysis of the insulin-induced L6 myotube secretome. Proteomics 9: 51-60, 2009.
42. Yuen DY, Dwyer RM, Matthews VB, Zhang L, Drew BG, Neill B, Kingwell BA, Clark MG, Rattigan S, Febbraio MA. Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor-alpha expression. Diabetes 58: 1086-1095, 2009.